|Bid||81.00 x 800|
|Ask||82.65 x 1000|
|Day's Range||80.37 - 83.71|
|52 Week Range||53.06 - 123.99|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.55|
In a note out Thursday, Stifel analyst Daniel Arias wrote that the company was “set up to deliver” in 2020, and that with shares down significantly in recent months, it’s a good time to buy Exact Sciences (ticker: EXAS). As of Thursday’s close, shares of Exact Sciences were up 25.6% so far this year, but down 33% over the past three months. The stock fell sharply in early September on news of a study that raised questions about the effectiveness of Cologuard, the company’s home fecal screen for colon cancer.
Exact Sciences Corporation (NASDAQ:EXAS) shareholders might be concerned after seeing the share price drop 29% in the...
Genomic Health chairman and CEO Kim Popovits is leaving the company as part of the combination of the two companies.
MADISON, Wisconsin, Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy, chairman and CEO of Exact Sciences. "We're excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey.
Data to be Presented at AASLD 2019, Abstract Selected for The Best of the Liver Meeting® BOSTON , Nov. 8, 2019 /PRNewswire/ -- (NASDAQ: EXAS) – A new study of 443 patients by Exact Sciences Corp. and ...
REDWOOD CITY, Calif., Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (EXAS) at a special meeting held earlier today. As previously announced, on July 29, 2019, Genomic Health and Exact Sciences entered into the merger agreement by which Exact Sciences will acquire Genomic Health in a cash and stock transaction. With the receipt of the required stockholder approval, Genomic Health and Exact Sciences expect to close the transaction on Friday, November 8 subject to satisfaction of the remaining customary closing conditions.
NEW YORK , Nov. 4, 2019 /PRNewswire/ -- Shenandoah Telecommunications Co. (NASD: SHEN) will replace Genomic Health Inc. (NASD: GHDX) in the S&P SmallCap 600 effective prior to the open of trading on Friday, ...
MADISON, Wis., Nov. 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 29) Cabaletta Bio Inc (NASDAQ: CABA ) Edwards Lifesciences ...
Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Chairman and CEO Kim Popovits has been in various leadership positions with the Redwood City company since 2002.
Third-quarter test volume for Cologuard is up to 456,000 completed tests, an increase of 89% compared with the same quarter in 2018.
MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company generated revenue of $218.8 million and screened approximately 456,000 people with Cologuard during the quarter ended September 30, 2019. "The Exact Sciences team delivered another strong quarter and most importantly, has screened more than 3 million people with Cologuard over the last 5 years," said Kevin Conroy, chairman and CEO of Exact Sciences.
MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- (EXAS) – Promising research from Exact Sciences Corp. and Mayo Clinic shows new methylation and protein markers detect colorectal cancer and advanced adenomas with high accuracy. Findings from the blinded, case-control study were presented at the American College of Gastroenterology's (ACG) 2019 Annual Scientific Meeting today. The study is part of an effort to increase specificity of Cologuard®, while maintaining its high level of sensitivity.
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers ...
MADISON, Wis., Oct. 14, 2019 /PRNewswire/ -- (EXAS) – Exact Sciences Corp. today announced that, in collaboration with Mayo Clinic, it has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. Voyage is a prospective, observational study designed to enroll more than 150,000 people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes. Voyage is one of the largest prospective, observational colorectal cancer screening studies ever conducted.